Tibet AIM Pharm Management

Management criteria checks 2/4

Tibet AIM Pharm's CEO is Ke Xu, appointed in Sep 2021, has a tenure of 2.67 years. directly owns 0.64% of the company’s shares, worth CN¥11.27M. The average tenure of the management team and the board of directors is 2.7 years and 2.7 years respectively.

Key information

Ke Xu

Chief executive officer

CN¥724.1k

Total compensation

CEO salary percentage	n/a
CEO tenure	2.7yrs
CEO ownership	0.6%
Management average tenure	2.7yrs
Board average tenure	2.7yrs

Recent management updates

Recent updates

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

May 02

Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%

Feb 29

CEO

Ke Xu (45 yo)

2.7yrs

Tenure

CN¥724,100

Compensation

Mr. Ke Xu serves as Chairman of Tibet AIM Pharm. Inc. since February 10, 2023. He serves as General Manager and Director of Tibet AIM Pharm.Inc. since September 13, 2021 and served as its Financial Direct...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ke Xu	GM & Chairman	2.7yrs	CN¥724.10k	0.64% CN¥ 11.3m
Yu Zhang	Deputy GM & Non-Independent Director	2.7yrs	CN¥301.20k	0.20% CN¥ 3.5m
Qianjin Li	Deputy GM & Secretary of the Board of Directors	2.7yrs	CN¥443.90k	0.096% CN¥ 1.7m
Zhou Min	Financial Director & Director	1.3yrs	no data	no data

2.7yrs

Average Tenure

44yo

Average Age

Experienced Management: 002826's management team is considered experienced (2.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ke Xu	GM & Chairman	2.7yrs	CN¥724.10k	0.64% CN¥ 11.3m
Yu Zhang	Deputy GM & Non-Independent Director	2.7yrs	CN¥301.20k	0.20% CN¥ 3.5m
Zhou Min	Financial Director & Director	1.3yrs	no data	no data
Zhan Zhou	Vice Chairman	9.4yrs	CN¥301.20k	7.53% CN¥ 133.1m
Ming Hu	Independent Director	2.7yrs	CN¥200.00k	no data
Xinggang Xiao	Independent Director	2.7yrs	CN¥200.00k	no data
Lan Feng	Independent Director	2.7yrs	CN¥200.00k	no data
Ling Li	Chairman of the Supervisory Board	2.7yrs	no data	0.24% CN¥ 4.2m
Zhongbin Wang	Non-Employee Supervisor	2.7yrs	no data	no data

2.7yrs

Average Tenure

45yo

Average Age

Experienced Board: 002826's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Tibet AIM Pharm Management

Management criteria checks 2/4

Key information

Recent management updates

Tibet AIM Pharm. Inc., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Tibet AIM Pharm. Inc., Annual General Meeting, May 18, 2022

Recent updates

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

Tibet AIM Pharm. Inc., Annual General Meeting, May 17, 2024

Tibet Aim Pharm. Inc. Proposes Final Dividend for 2023

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.04 in 1Q 2023)

Investor sentiment deteriorates as stock falls 19%

Tibet AIM Pharm. Inc. to Report Q1, 2024 Results on Apr 26, 2024

Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Tibet AIM Pharm. Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Tibet AIM Pharm. Inc. (SZSE:002826) announces an Equity Buyback for CNY 100 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.066 (vs CN¥0.087 in 3Q 2022)

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.019 in 2Q 2022)

Tibet AIM Pharm. Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 07 July 2023

Tibet AIM Pharm. Inc. Approves Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.22 in FY 2021)

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.042 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.021 in 2Q 2021)

Tibet AIM Pharm. Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 8 July 2022

Tibet AIM Pharm. Inc. Approves 2021 Profit Distribution Plan

Full year 2021 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in FY 2020)

High number of new and inexperienced directors

Tibet AIM Pharm. Inc., Annual General Meeting, May 18, 2022

Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.042 (vs CN¥0.02 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.041 in 2Q 2020)

Tibet AIM Pharm. Inc. (SZSE:002826) agreed to acquire 51% stake in Inner Mongolia Bositai Enterprise Management Service Co., Ltd. for CNY 30.6 million.

Tibet AIM Pharm. Inc. Approves Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.03 in 1Q 2020)

Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for 2020

New 90-day low: CN¥8.25

New 90-day low: CN¥9.55

New 90-day low: CN¥10.42

New 90-day low: CN¥10.82

Third quarter earnings released

New 90-day low: CN¥11.11

Earnings released

Tibet AIM Pharm. Inc. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age